MA39152B1 - Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine - Google Patents

Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine

Info

Publication number
MA39152B1
MA39152B1 MA39152A MA39152A MA39152B1 MA 39152 B1 MA39152 B1 MA 39152B1 MA 39152 A MA39152 A MA 39152A MA 39152 A MA39152 A MA 39152A MA 39152 B1 MA39152 B1 MA 39152B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
orexin receptor
substituted cyclopentanes
cyclopentanes
substituted
Prior art date
Application number
MA39152A
Other languages
English (en)
Other versions
MA39152A1 (fr
Inventor
Charlotte Fieldhouse
Angela Glen
Stephanie Maine
Tatsuhiko Fujimoto
John Stephen Robinson
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39152A1 publication Critical patent/MA39152A1/fr
Publication of MA39152B1 publication Critical patent/MA39152B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des composés de formule (i), ainsi que leurs sels pharmaceutiquement acceptables. Dans la formule (i), l,x, r
MA39152A 2014-02-20 2015-02-19 Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine MA39152B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14156011 2014-02-20
PCT/GB2015/050480 WO2015124932A1 (fr) 2014-02-20 2015-02-19 Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine

Publications (2)

Publication Number Publication Date
MA39152A1 MA39152A1 (fr) 2017-11-30
MA39152B1 true MA39152B1 (fr) 2019-09-30

Family

ID=50115776

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39152A MA39152B1 (fr) 2014-02-20 2015-02-19 Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine

Country Status (27)

Country Link
US (3) US10011588B2 (fr)
EP (1) EP3107898B1 (fr)
JP (1) JP6433505B2 (fr)
KR (1) KR20160121572A (fr)
CN (1) CN106164047B (fr)
AR (1) AR099495A1 (fr)
AU (1) AU2015220551B2 (fr)
CA (1) CA2938855C (fr)
CL (1) CL2016002084A1 (fr)
CR (1) CR20160374A (fr)
EA (1) EA033758B1 (fr)
EC (1) ECSP16074478A (fr)
ES (1) ES2855499T3 (fr)
GE (1) GEP20186910B (fr)
IL (1) IL247194B (fr)
MA (1) MA39152B1 (fr)
MX (1) MX2016010848A (fr)
MY (1) MY182564A (fr)
PE (1) PE20161444A1 (fr)
PH (1) PH12016501624A1 (fr)
PL (1) PL3107898T3 (fr)
SG (2) SG11201605298RA (fr)
TN (1) TN2016000263A1 (fr)
TW (1) TW201613864A (fr)
UA (1) UA119552C2 (fr)
UY (1) UY36003A (fr)
WO (1) WO2015124932A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CA3016706A1 (fr) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methodes de traitement de la depression a l'aide d'antagonistes de recepteurs de l'orexine-2
EP3436054B2 (fr) 2016-09-13 2022-07-27 Allergan, Inc. Compositions de toxines clostridiales non protéiques
CN106580998B (zh) * 2016-12-08 2017-11-07 青岛市市立医院 一种治疗肾性高血压的药物组合物
CN107434788B (zh) * 2017-09-11 2018-06-15 威海迪素制药有限公司 一种格列吡嗪的制备方法
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
CN113999142B (zh) * 2021-11-29 2023-01-24 蚌埠中实化学技术有限公司 一种手性N-Boc-反式-1,2-环己二胺的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0777671B1 (fr) 1994-08-24 2000-04-26 Astra Aktiebolag Composes spiro-azabicycliques utiles en therapie
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
KR100915263B1 (ko) 2001-05-18 2009-09-03 아스트라제네카 아베 4(페닐-피페라지닐-메틸)벤즈아미드 유도체 및 통증, 불안증 또는 위장관 장애 치료를 위한 이들의 용도
BR0210075A (pt) 2001-06-01 2004-08-17 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
EP1399441B1 (fr) * 2001-06-28 2006-07-05 Smithkline Beecham Plc Derives d'amine cycliques n-aroyle utilises comme antagonistes du recepteur de l'orexine
GB0130341D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
CA2482313A1 (fr) 2002-04-18 2003-10-23 Astrazeneca Ab Composes heterocycliques
AU2003224545B2 (en) 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds
ATE484508T1 (de) 2002-04-18 2010-10-15 Astrazeneca Ab Furylverbindungen
EP1505966A4 (fr) 2002-05-10 2006-08-30 Bristol Myers Squibb Co Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
US20080090863A1 (en) * 2004-09-30 2008-04-17 Taisho Pharmaceutical Co., Ltd. Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
DK1846354T3 (da) 2005-01-14 2010-08-16 Allergan Inc Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande
CA2609203A1 (fr) * 2005-05-23 2006-11-30 Merck & Co., Inc Antagonistes des recepteurs d'orexine a base de bis-amide de proline
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
EP2049110B1 (fr) * 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
WO2008038841A1 (fr) 2006-09-30 2008-04-03 Japan Tobacco Inc. Dérivé de thiadiazolone et utilisation de celui-ci
UY30796A1 (es) 2006-12-15 2008-07-31 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
CA2672727A1 (fr) 2006-12-21 2008-07-03 Abbott Laboratories Composes d'agonistes et d'antagonistes des recepteurs de sphingosine-1-phosphate
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
PE20090441A1 (es) * 2007-07-03 2009-05-08 Glaxo Group Ltd DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
JP5395808B2 (ja) 2007-12-21 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体
JP2010155827A (ja) * 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
CN102414184A (zh) * 2009-05-12 2012-04-11 埃科特莱茵药品有限公司 新型的噁唑烷酮衍生物及其作为食欲素受体拮抗剂的用途
US8080541B2 (en) * 2009-08-27 2011-12-20 Hoffman-La Roche Inc. Carbocyclic GlyT-1 receptor antagonists
BR112013013695A2 (pt) * 2010-12-17 2016-09-13 Taisho Pharmaceutical Co Ltd derivado de pirazol
JP5987005B2 (ja) * 2011-02-18 2016-09-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体
NZ703448A (en) * 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014124230A2 (fr) * 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Inhibiteurs d'erk et leurs utilisations
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
MA39229A1 (fr) 2014-02-20 2018-01-31 Takeda Pharmaceuticals Co Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途

Also Published As

Publication number Publication date
GEP20186910B (en) 2018-10-25
PL3107898T3 (pl) 2021-06-14
PE20161444A1 (es) 2017-01-06
CA2938855A1 (fr) 2015-08-27
AU2015220551A1 (en) 2016-07-14
SG10201908582TA (en) 2019-11-28
UY36003A (es) 2015-09-30
IL247194B (en) 2019-12-31
EP3107898A1 (fr) 2016-12-28
EP3107898B1 (fr) 2021-01-06
WO2015124932A1 (fr) 2015-08-27
US20150232460A1 (en) 2015-08-20
US20180282309A1 (en) 2018-10-04
JP6433505B2 (ja) 2018-12-05
US20170066744A1 (en) 2017-03-09
CR20160374A (es) 2017-01-27
MY182564A (en) 2021-01-25
SG11201605298RA (en) 2016-07-28
EA033758B1 (ru) 2019-11-22
JP2017506635A (ja) 2017-03-09
ES2855499T3 (es) 2021-09-23
KR20160121572A (ko) 2016-10-19
US9156829B2 (en) 2015-10-13
US10011588B2 (en) 2018-07-03
UA119552C2 (uk) 2019-07-10
MA39152A1 (fr) 2017-11-30
PH12016501624A1 (en) 2016-11-07
TW201613864A (en) 2016-04-16
ECSP16074478A (es) 2018-07-31
CL2016002084A1 (es) 2017-09-08
EA201691674A1 (ru) 2017-02-28
MX2016010848A (es) 2017-01-23
CA2938855C (fr) 2022-06-21
CN106164047A (zh) 2016-11-23
CN106164047B (zh) 2019-04-16
IL247194A0 (en) 2016-09-29
US10689373B2 (en) 2020-06-23
AU2015220551B2 (en) 2018-10-25
AR099495A1 (es) 2016-07-27
TN2016000263A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
MA44820B1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
MA40302A1 (fr) Dérivés de carbazole
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
RS54730B1 (sr) Inhibitori beta sekretaze
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201691141A1 (ru) Соединения против ccr6
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MA50093B1 (fr) Composé pentacyclique
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39305A3 (fr) Dérivés d'éthynyle
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона